Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/4498
Title: Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-alpha 2A and ribavirin therapy in patients with chronic hepatitis C
Authors: ARAUJO, Ana RuthPERUHYPE-MAGALHAES, VanessaCOELHO-DOS-REIS, Jordana Grazziela AlvesCHAVES, Laura Patricia VianaLIMA, Tatiane Amabili dePIMENTEL, Joao Paulo DinizPAULA, Lucia deALMEIDA, Carlos Mauricio deTARRAGO, Andrea MonteiroTATENO, AdrianaLEVI, Jose EduardoTEIXEIRA-CARVALHO, AndreaMARTINS-FILHO, Olindo de AssisLIRA, Edson da FonsecaTORRES, Katia LuzTALHARI, SinesioMALHEIRO, Adriana
Citation: IMMUNOLOGY LETTERS, v.154, n.1-2, p.61-69, 2013
Abstract: Several efforts have been made to establish novel biomarkers with relevant predictive values to monitor HCV-infected patients under pegilated Interferon-alpha 2A-(PEG-IFN-alpha 2A)/ribavirin therapy. The aim of this study was to monitor the kinetics of HCV viral load, serum levels of pro-inflammatory/regulatory cytokines and leukocyte activation status before and after PEG-IFN-alpha 2A/ribavirin therapy in 52 volunteers, including 12 chronic HCV patients and 40 controls. The HCV viral load, serum levels of cytokines (IL-8/IL-6/TNF-alpha/IL-12/IFN-gamma/IL-4/IL-10) and the phenotype of peripheral blood leukocytes were evaluated before and after 4, 12 and 24 weeks following the PEG-IFN-alpha 2A/ribavirin therapy. Our results demonstrated that sustained virological response-(SVR) is associated with early decrease in the viral load after 4 weeks of treatment. The presence of a modulated pro-inflammatory profile at baseline favors SVR, whereas a strong inflammatory response at baseline predisposes to therapeutic failure. Furthermore, a time-dependent increase on serum IL-12 levels in patients under treatment is critical to support the SVR, while the early predominance of IL-10 correlates to late virological relapse. On the other hand, a broad but unguided ""cytokine storm"" is observed in the non-responder HCV patients after 12 weeks of treatment. Corroborating these findings, monocyte/lymphocyte activation at baseline is associated with the non-responders to therapy whereas high CDS+ T-cell numbers associate with SVR. All in all, these data suggest that the baseline pattern of serum pro-inflammatory/regulatory cytokines and the immunological activation status of chronic HCV patients undergoing PEG-IFN-alpha 2A/ribavirin therapy are closely related with the therapeutic response.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - IMT
Instituto de Medicina Tropical - IMT

Artigos e Materiais de Revistas Científicas - LIM/52
LIM/52 - Laboratório de Virologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_TATENO_Dual_role_of_IL_12_in_the_therapeutic_2013.PDF
  Restricted Access
publishedVersion (English)1.22 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.